person · Reporting owner

SANDS FRANK M.

Disclosed activity across 2 companies

Tapewire entity: 72648
SEC CIK: 0001870494

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Inhibikase Therapeutics, Inc.IKT · Entity 5838	10% owner	November 21, 2025	November 24, 2025

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Inhibikase Therapeutics, Inc.

Report date November 21, 2025 · Filed November 24, 2025

Jointly reported with Sands Capital Life Sciences Pulse Fund II, L.P., Sands Capital Alternatives, LLC

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	13,018,965	Reported balance After 2025-11-21 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2025-11-21 · Purchase · Acquired 2,068,965 · Balance 13,018,965 F5: The securities reported herein were acquired in an underwritten public offering by the Issuer at the public offering price of $1.45 per share. F1: This report does not include a Series A-1 warrant to purchase 5,475,000 shares of Common Stock (the "Series A-1 Warrant") or a Series B-1 warrant to purchase 10,068,120 shares of Common Stock (the "Series B-1 Warrant"), in each case held by Sands Capital Life Sciences Pulse Fund II, L.P. ("Sands Pulse Fund II"), each of which was purchased by Sands Pulse Fund II from the Issuer pursuant to that certain securities purchase agreement dated October 9, 2024 between the Issuer and, among certain other institutional and accredited investors, Sands Pulse Fund II (the "Purchase Agreement"). F2: (Continued from footnote 1) The Series A-1 Warrant is exercisable on the earlier of (a) the 75th calendar day following the initial filing date of the registration statement covering the resale of the shares of Common Stock underlying the Series A-1 warrants and Series B-1 warrants issued pursuant to the Purchase Agreement (the "Warrant Initial Registration Statement") if the Securities and Exchange Commission ("SEC") notifies the Issuer that it will "review" the Warrant Initial Registration Statement and (b) the fifth business day after the date the Issuer is notified (orally or in writing, whichever is earlier) by the SEC that the Warrant Initial Registration Statement will not be "reviewed" or(even if previously subject to review pursuant to clause (a) of this sentence) will not be subject to further review (the "Initial Exercise Date"). The Series B-1 Warrant is exercisable on the Initial Exercise Date, provided that, to the extent exercisable, F3: (Continued from footnote 2) the Series A-1 Warrant issued to Sands Pulse Fund II has been exercised in full either by Sands Pulse Fund II or its transferee permitted by the terms of the Series A-1 Warrant. The Series A-1 Warrant and the Series B-1 Warrant each provide that the holder of such warrant will not have the right to exercise any portion of such warrant if such holder, together with its affiliates, would beneficially own in excess of 19.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise. The Reporting Persons each disclaim beneficial ownership of the shares of Common Stock underlying each of the Series A-1 Warrant and Series B-1Warrant because neither the Series A-1 Warrant nor the Series B-1 Warrant is exercisable within 60 days of this filing and such date is not determinable at this time. F4: Represents shares of common stock, par value $0.001, of the Issuer ("Common Stock") held by Sands Pulse Fund II. Sands Capital Alternatives, LLC ("Sands Alternatives") is the investment manager of Sands Pulse Fund II. Sands Capital Life Sciences Pulse Fund II-GP, L.P. ("Sands Pulse GP L.P.") is the general partner of Sands Pulse Fund II. Sands Capital Life Sciences Pulse Fund II-GP, LLC ("Sands Pulse GP LLC") is the general partner of Sands Pulse GP L.P. Sands Alternatives, Sands Pulse GP L.P. and Sands Pulse GPLLC each disclaim beneficial ownership of such securities except to the extent of their relative pecuniary interest therein. Frank M. Sands holds ultimate voting and investment power over these securities and may be deemed to beneficially own the securities. Mr. Sands disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: This report does not include a Series A-1 warrant to purchase 5,475,000 shares of Common Stock (the "Series A-1 Warrant") or a Series B-1 warrant to purchase 10,068,120 shares of Common Stock (the "Series B-1 Warrant"), in each case held by Sands Capital Life Sciences Pulse Fund II, L.P. ("Sands Pulse Fund II"), each of which was purchased by Sands Pulse Fund II from the Issuer pursuant to that certain securities purchase agreement dated October 9, 2024 between the Issuer and, among certain other institutional and accredited investors, Sands Pulse Fund II (the "Purchase Agreement").

F2: (Continued from footnote 1) The Series A-1 Warrant is exercisable on the earlier of (a) the 75th calendar day following the initial filing date of the registration statement covering the resale of the shares of Common Stock underlying the Series A-1 warrants and Series B-1 warrants issued pursuant to the Purchase Agreement (the "Warrant Initial Registration Statement") if the Securities and Exchange Commission ("SEC") notifies the Issuer that it will "review" the Warrant Initial Registration Statement and (b) the fifth business day after the date the Issuer is notified (orally or in writing, whichever is earlier) by the SEC that the Warrant Initial Registration Statement will not be "reviewed" or(even if previously subject to review pursuant to clause (a) of this sentence) will not be subject to further review (the "Initial Exercise Date"). The Series B-1 Warrant is exercisable on the Initial Exercise Date, provided that, to the extent exercisable,

F3: (Continued from footnote 2) the Series A-1 Warrant issued to Sands Pulse Fund II has been exercised in full either by Sands Pulse Fund II or its transferee permitted by the terms of the Series A-1 Warrant. The Series A-1 Warrant and the Series B-1 Warrant each provide that the holder of such warrant will not have the right to exercise any portion of such warrant if such holder, together with its affiliates, would beneficially own in excess of 19.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise. The Reporting Persons each disclaim beneficial ownership of the shares of Common Stock underlying each of the Series A-1 Warrant and Series B-1Warrant because neither the Series A-1 Warrant nor the Series B-1 Warrant is exercisable within 60 days of this filing and such date is not determinable at this time.

F4: Represents shares of common stock, par value $0.001, of the Issuer ("Common Stock") held by Sands Pulse Fund II. Sands Capital Alternatives, LLC ("Sands Alternatives") is the investment manager of Sands Pulse Fund II. Sands Capital Life Sciences Pulse Fund II-GP, L.P. ("Sands Pulse GP L.P.") is the general partner of Sands Pulse Fund II. Sands Capital Life Sciences Pulse Fund II-GP, LLC ("Sands Pulse GP LLC") is the general partner of Sands Pulse GP L.P. Sands Alternatives, Sands Pulse GP L.P. and Sands Pulse GPLLC each disclaim beneficial ownership of such securities except to the extent of their relative pecuniary interest therein. Frank M. Sands holds ultimate voting and investment power over these securities and may be deemed to beneficially own the securities. Mr. Sands disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

F5: The securities reported herein were acquired in an underwritten public offering by the Issuer at the public offering price of $1.45 per share.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Acumen Pharmaceuticals, Inc.

Report date July 06, 2021 · Filed July 08, 2021

Jointly reported with Sands Capital Ventures Discovery Fund III, L.P., Sands Capital Global Venture Fund II, L.P., Sands Capital Life Sciences Pulse Fund, LLC

Section 16 reporting ended · disclosed 2021-07-08. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	1,124,729	Reported balance After 2021-07-06 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2021-07-06 · Conversion · Acquired 1,124,729 · Balance 1,124,729 F1: Each share of Series A-1 Preferred Stock and each share of Series B Preferred Stock automatically converted into one share of Common Stock of the Issuer upon the closing of the Issuer's initial public offering. F3: Consists of 1,124,719 shares of Common Stock held by Sands Capital Ventures Discovery Fund III, L.P. ("Sands Discovery Fund "). Sands Capital Ventures Discovery Fund III-GP, LLC ("Sands Discovery GP") is the general partner of Sands Discovery Fund. Sands Discovery GP disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. F5: Frank M. Sands holds ultimate voting and investment power over securities held by Sands Discovery Fund, Sands Venture Fund and Sands Pulse Fund. Mr. Sands disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.
Common StockSEC Table I · non-derivative	Direct	2,967,075	Reported balance After 2021-07-06 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 2 · 2021-07-06 · Conversion · Acquired 1,842,346 · Balance 2,967,075 F1: Each share of Series A-1 Preferred Stock and each share of Series B Preferred Stock automatically converted into one share of Common Stock of the Issuer upon the closing of the Issuer's initial public offering. F4: Consists of 921,173 shares of Common Stock held by Sands Venture Fund and 921,173 shares of Common Stock held by Sands Pulse Fund. Sands Capital Global Venture Fund II-GP, L.P. ("Sands Venture GP L.P.") is the general partner of Sands Venture Fund and Sands Capital Global Venture Discovery Fund II-GP, LLC ("Sands Venture GP LLC") is the general partner of Sands Venture GP L.P. Sands Venture GP L.P. and Sands Venture GP LLC each disclaims beneficial ownership of such securities except to the extent of its respective pecuniary interest therein. F5: Frank M. Sands holds ultimate voting and investment power over securities held by Sands Discovery Fund, Sands Venture Fund and Sands Pulse Fund. Mr. Sands disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.
Common StockSEC Table I · non-derivative	Direct	3,417,075	Reported balance After 2021-07-06 transaction · row 3 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 3 · 2021-07-06 · Purchase · Acquired 450,000 · Balance 3,417,075 F2: Represents 225,000 shares of Common Stock acquired by Sands Capital Global Venture Fund II, L.P. ("Sands Venture Fund") and 225,000 shares of Common Stock acquired by ands Capital Life Sciences Pulse Fund ("Sands Pulse Fund") in connection with the closing of the Issuer's initial public offering. F4: Consists of 921,173 shares of Common Stock held by Sands Venture Fund and 921,173 shares of Common Stock held by Sands Pulse Fund. Sands Capital Global Venture Fund II-GP, L.P. ("Sands Venture GP L.P.") is the general partner of Sands Venture Fund and Sands Capital Global Venture Discovery Fund II-GP, LLC ("Sands Venture GP LLC") is the general partner of Sands Venture GP L.P. Sands Venture GP L.P. and Sands Venture GP LLC each disclaims beneficial ownership of such securities except to the extent of its respective pecuniary interest therein. F5: Frank M. Sands holds ultimate voting and investment power over securities held by Sands Discovery Fund, Sands Venture Fund and Sands Pulse Fund. Mr. Sands disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.
Series A-1 Preferred StockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2021-07-06 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2021-07-06 · Conversion · Disposed 1,124,729 · Balance 0 F1: Each share of Series A-1 Preferred Stock and each share of Series B Preferred Stock automatically converted into one share of Common Stock of the Issuer upon the closing of the Issuer's initial public offering. F3: Consists of 1,124,719 shares of Common Stock held by Sands Capital Ventures Discovery Fund III, L.P. ("Sands Discovery Fund "). Sands Capital Ventures Discovery Fund III-GP, LLC ("Sands Discovery GP") is the general partner of Sands Discovery Fund. Sands Discovery GP disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. F5: Frank M. Sands holds ultimate voting and investment power over securities held by Sands Discovery Fund, Sands Venture Fund and Sands Pulse Fund. Mr. Sands disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.
Series B Preferred StockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2021-07-06 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2021-07-06 · Conversion · Disposed 1,842,346 · Balance 0 F1: Each share of Series A-1 Preferred Stock and each share of Series B Preferred Stock automatically converted into one share of Common Stock of the Issuer upon the closing of the Issuer's initial public offering. F4: Consists of 921,173 shares of Common Stock held by Sands Venture Fund and 921,173 shares of Common Stock held by Sands Pulse Fund. Sands Capital Global Venture Fund II-GP, L.P. ("Sands Venture GP L.P.") is the general partner of Sands Venture Fund and Sands Capital Global Venture Discovery Fund II-GP, LLC ("Sands Venture GP LLC") is the general partner of Sands Venture GP L.P. Sands Venture GP L.P. and Sands Venture GP LLC each disclaims beneficial ownership of such securities except to the extent of its respective pecuniary interest therein. F5: Frank M. Sands holds ultimate voting and investment power over securities held by Sands Discovery Fund, Sands Venture Fund and Sands Pulse Fund. Mr. Sands disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: Each share of Series A-1 Preferred Stock and each share of Series B Preferred Stock automatically converted into one share of Common Stock of the Issuer upon the closing of the Issuer's initial public offering.

F2: Represents 225,000 shares of Common Stock acquired by Sands Capital Global Venture Fund II, L.P. ("Sands Venture Fund") and 225,000 shares of Common Stock acquired by ands Capital Life Sciences Pulse Fund ("Sands Pulse Fund") in connection with the closing of the Issuer's initial public offering.

F3: Consists of 1,124,719 shares of Common Stock held by Sands Capital Ventures Discovery Fund III, L.P. ("Sands Discovery Fund "). Sands Capital Ventures Discovery Fund III-GP, LLC ("Sands Discovery GP") is the general partner of Sands Discovery Fund. Sands Discovery GP disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.

F4: Consists of 921,173 shares of Common Stock held by Sands Venture Fund and 921,173 shares of Common Stock held by Sands Pulse Fund. Sands Capital Global Venture Fund II-GP, L.P. ("Sands Venture GP L.P.") is the general partner of Sands Venture Fund and Sands Capital Global Venture Discovery Fund II-GP, LLC ("Sands Venture GP LLC") is the general partner of Sands Venture GP L.P. Sands Venture GP L.P. and Sands Venture GP LLC each disclaims beneficial ownership of such securities except to the extent of its respective pecuniary interest therein.

F5: Frank M. Sands holds ultimate voting and investment power over securities held by Sands Discovery Fund, Sands Venture Fund and Sands Pulse Fund. Mr. Sands disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
November 21, 2025 Filed Nov 24, 2025 20:47 UTC	Inhibikase Therapeutics, Inc. IKT · Entity 5838	PurchaseCommon Stock	2,068,965	$1.45	$2,999,999.25	Disclosure SEC source: 0001875620-25-000025 · primary_doc.xml · nonDerivative · entry 1 Sands Capital Life Sciences Pulse Fund II, L.P. · CIK 0001875620 · 10% owner Sands Capital Alternatives, LLC · CIK 0001846444 · 10% owner SANDS FRANK M. · CIK 0001870494 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,018,965 F5 · kind: The securities reported herein were acquired in an underwritten public offering by the Issuer at the public offering price of $1.45 per share. F1 · balance_after: This report does not include a Series A-1 warrant to purchase 5,475,000 shares of Common Stock (the "Series A-1 Warrant") or a Series B-1 warrant to purchase 10,068,120 shares of Common Stock (the "Series B-1 Warrant"), in each case held by Sands Capital Life Sciences Pulse Fund II, L.P. ("Sands Pulse Fund II"), each of which was purchased by Sands Pulse Fund II from the Issuer pursuant to that certain securities purchase agreement dated October 9, 2024 between the Issuer and, among certain other institutional and accredited investors, Sands Pulse Fund II (the "Purchase Agreement"). F2 · balance_after: (Continued from footnote 1) The Series A-1 Warrant is exercisable on the earlier of (a) the 75th calendar day following the initial filing date of the registration statement covering the resale of the shares of Common Stock underlying the Series A-1 warrants and Series B-1 warrants issued pursuant to the Purchase Agreement (the "Warrant Initial Registration Statement") if the Securities and Exchange Commission ("SEC") notifies the Issuer that it will "review" the Warrant Initial Registration Statement and (b) the fifth business day after the date the Issuer is notified (orally or in writing, whichever is earlier) by the SEC that the Warrant Initial Registration Statement will not be "reviewed" or(even if previously subject to review pursuant to clause (a) of this sentence) will not be subject to further review (the "Initial Exercise Date"). The Series B-1 Warrant is exercisable on the Initial Exercise Date, provided that, to the extent exercisable, F3 · balance_after: (Continued from footnote 2) the Series A-1 Warrant issued to Sands Pulse Fund II has been exercised in full either by Sands Pulse Fund II or its transferee permitted by the terms of the Series A-1 Warrant. The Series A-1 Warrant and the Series B-1 Warrant each provide that the holder of such warrant will not have the right to exercise any portion of such warrant if such holder, together with its affiliates, would beneficially own in excess of 19.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise. The Reporting Persons each disclaim beneficial ownership of the shares of Common Stock underlying each of the Series A-1 Warrant and Series B-1Warrant because neither the Series A-1 Warrant nor the Series B-1 Warrant is exercisable within 60 days of this filing and such date is not determinable at this time. F4 · ownership.direct: Represents shares of common stock, par value $0.001, of the Issuer ("Common Stock") held by Sands Pulse Fund II. Sands Capital Alternatives, LLC ("Sands Alternatives") is the investment manager of Sands Pulse Fund II. Sands Capital Life Sciences Pulse Fund II-GP, L.P. ("Sands Pulse GP L.P.") is the general partner of Sands Pulse Fund II. Sands Capital Life Sciences Pulse Fund II-GP, LLC ("Sands Pulse GP LLC") is the general partner of Sands Pulse GP L.P. Sands Alternatives, Sands Pulse GP L.P. and Sands Pulse GPLLC each disclaim beneficial ownership of such securities except to the extent of their relative pecuniary interest therein. Frank M. Sands holds ultimate voting and investment power over these securities and may be deemed to beneficially own the securities. Mr. Sands disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document
July 06, 2021 Filed Jul 8, 2021 21:21 UTC	Acumen Pharmaceuticals, Inc. ABOS · Entity 6281	ConversionSeries B Preferred Stock · Derivative	1,842,346	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-21-027891 · doc4.xml · derivative · entry 5 Sands Capital Ventures Discovery Fund III, L.P. · CIK 0001870491 · 10% owner Sands Capital Global Venture Fund II, L.P. · CIK 0001870493 · 10% owner Sands Capital Life Sciences Pulse Fund, LLC · CIK 0001870490 · 10% owner SANDS FRANK M. · CIK 0001870494 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,842,346 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A-1 Preferred Stock and each share of Series B Preferred Stock automatically converted into one share of Common Stock of the Issuer upon the closing of the Issuer's initial public offering. F1 · price: Each share of Series A-1 Preferred Stock and each share of Series B Preferred Stock automatically converted into one share of Common Stock of the Issuer upon the closing of the Issuer's initial public offering. F1 · derivative.exercise_date: Each share of Series A-1 Preferred Stock and each share of Series B Preferred Stock automatically converted into one share of Common Stock of the Issuer upon the closing of the Issuer's initial public offering. F1 · derivative.expiration_date: Each share of Series A-1 Preferred Stock and each share of Series B Preferred Stock automatically converted into one share of Common Stock of the Issuer upon the closing of the Issuer's initial public offering. F4 · ownership.direct: Consists of 921,173 shares of Common Stock held by Sands Venture Fund and 921,173 shares of Common Stock held by Sands Pulse Fund. Sands Capital Global Venture Fund II-GP, L.P. ("Sands Venture GP L.P.") is the general partner of Sands Venture Fund and Sands Capital Global Venture Discovery Fund II-GP, LLC ("Sands Venture GP LLC") is the general partner of Sands Venture GP L.P. Sands Venture GP L.P. and Sands Venture GP LLC each disclaims beneficial ownership of such securities except to the extent of its respective pecuniary interest therein. F5 · ownership.direct: Frank M. Sands holds ultimate voting and investment power over securities held by Sands Discovery Fund, Sands Venture Fund and Sands Pulse Fund. Mr. Sands disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document
July 06, 2021 Filed Jul 8, 2021 21:21 UTC	Acumen Pharmaceuticals, Inc. ABOS · Entity 6281	ConversionSeries A-1 Preferred Stock · Derivative	1,124,729	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-21-027891 · doc4.xml · derivative · entry 4 Sands Capital Ventures Discovery Fund III, L.P. · CIK 0001870491 · 10% owner Sands Capital Global Venture Fund II, L.P. · CIK 0001870493 · 10% owner Sands Capital Life Sciences Pulse Fund, LLC · CIK 0001870490 · 10% owner SANDS FRANK M. · CIK 0001870494 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,124,729 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A-1 Preferred Stock and each share of Series B Preferred Stock automatically converted into one share of Common Stock of the Issuer upon the closing of the Issuer's initial public offering. F1 · price: Each share of Series A-1 Preferred Stock and each share of Series B Preferred Stock automatically converted into one share of Common Stock of the Issuer upon the closing of the Issuer's initial public offering. F1 · derivative.exercise_date: Each share of Series A-1 Preferred Stock and each share of Series B Preferred Stock automatically converted into one share of Common Stock of the Issuer upon the closing of the Issuer's initial public offering. F1 · derivative.expiration_date: Each share of Series A-1 Preferred Stock and each share of Series B Preferred Stock automatically converted into one share of Common Stock of the Issuer upon the closing of the Issuer's initial public offering. F3 · ownership.direct: Consists of 1,124,719 shares of Common Stock held by Sands Capital Ventures Discovery Fund III, L.P. ("Sands Discovery Fund "). Sands Capital Ventures Discovery Fund III-GP, LLC ("Sands Discovery GP") is the general partner of Sands Discovery Fund. Sands Discovery GP disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. F5 · ownership.direct: Frank M. Sands holds ultimate voting and investment power over securities held by Sands Discovery Fund, Sands Venture Fund and Sands Pulse Fund. Mr. Sands disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document
July 06, 2021 Filed Jul 8, 2021 21:21 UTC	Acumen Pharmaceuticals, Inc. ABOS · Entity 6281	PurchaseCommon Stock	450,000	$14.88	$6,696,000.00	Disclosure SEC source: 0000899243-21-027891 · doc4.xml · nonDerivative · entry 3 Sands Capital Ventures Discovery Fund III, L.P. · CIK 0001870491 · 10% owner Sands Capital Global Venture Fund II, L.P. · CIK 0001870493 · 10% owner Sands Capital Life Sciences Pulse Fund, LLC · CIK 0001870490 · 10% owner SANDS FRANK M. · CIK 0001870494 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,417,075 F2 · kind: Represents 225,000 shares of Common Stock acquired by Sands Capital Global Venture Fund II, L.P. ("Sands Venture Fund") and 225,000 shares of Common Stock acquired by ands Capital Life Sciences Pulse Fund ("Sands Pulse Fund") in connection with the closing of the Issuer's initial public offering. F4 · ownership.direct: Consists of 921,173 shares of Common Stock held by Sands Venture Fund and 921,173 shares of Common Stock held by Sands Pulse Fund. Sands Capital Global Venture Fund II-GP, L.P. ("Sands Venture GP L.P.") is the general partner of Sands Venture Fund and Sands Capital Global Venture Discovery Fund II-GP, LLC ("Sands Venture GP LLC") is the general partner of Sands Venture GP L.P. Sands Venture GP L.P. and Sands Venture GP LLC each disclaims beneficial ownership of such securities except to the extent of its respective pecuniary interest therein. F5 · ownership.direct: Frank M. Sands holds ultimate voting and investment power over securities held by Sands Discovery Fund, Sands Venture Fund and Sands Pulse Fund. Mr. Sands disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document
July 06, 2021 Filed Jul 8, 2021 21:21 UTC	Acumen Pharmaceuticals, Inc. ABOS · Entity 6281	ConversionCommon Stock	1,842,346	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-21-027891 · doc4.xml · nonDerivative · entry 2 Sands Capital Ventures Discovery Fund III, L.P. · CIK 0001870491 · 10% owner Sands Capital Global Venture Fund II, L.P. · CIK 0001870493 · 10% owner Sands Capital Life Sciences Pulse Fund, LLC · CIK 0001870490 · 10% owner SANDS FRANK M. · CIK 0001870494 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,967,075 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series A-1 Preferred Stock and each share of Series B Preferred Stock automatically converted into one share of Common Stock of the Issuer upon the closing of the Issuer's initial public offering. F4 · ownership.direct: Consists of 921,173 shares of Common Stock held by Sands Venture Fund and 921,173 shares of Common Stock held by Sands Pulse Fund. Sands Capital Global Venture Fund II-GP, L.P. ("Sands Venture GP L.P.") is the general partner of Sands Venture Fund and Sands Capital Global Venture Discovery Fund II-GP, LLC ("Sands Venture GP LLC") is the general partner of Sands Venture GP L.P. Sands Venture GP L.P. and Sands Venture GP LLC each disclaims beneficial ownership of such securities except to the extent of its respective pecuniary interest therein. F5 · ownership.direct: Frank M. Sands holds ultimate voting and investment power over securities held by Sands Discovery Fund, Sands Venture Fund and Sands Pulse Fund. Mr. Sands disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document
July 06, 2021 Filed Jul 8, 2021 21:21 UTC	Acumen Pharmaceuticals, Inc. ABOS · Entity 6281	ConversionCommon Stock	1,124,729	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-21-027891 · doc4.xml · nonDerivative · entry 1 Sands Capital Ventures Discovery Fund III, L.P. · CIK 0001870491 · 10% owner Sands Capital Global Venture Fund II, L.P. · CIK 0001870493 · 10% owner Sands Capital Life Sciences Pulse Fund, LLC · CIK 0001870490 · 10% owner SANDS FRANK M. · CIK 0001870494 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,124,729 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series A-1 Preferred Stock and each share of Series B Preferred Stock automatically converted into one share of Common Stock of the Issuer upon the closing of the Issuer's initial public offering. F3 · ownership.direct: Consists of 1,124,719 shares of Common Stock held by Sands Capital Ventures Discovery Fund III, L.P. ("Sands Discovery Fund "). Sands Capital Ventures Discovery Fund III-GP, LLC ("Sands Discovery GP") is the general partner of Sands Discovery Fund. Sands Discovery GP disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. F5 · ownership.direct: Frank M. Sands holds ultimate voting and investment power over securities held by Sands Discovery Fund, Sands Venture Fund and Sands Pulse Fund. Mr. Sands disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.